MA49627A - Associations pharmaceutiques comprenant un anticorps anti-bst-1 et un analogue de cytidine - Google Patents
Associations pharmaceutiques comprenant un anticorps anti-bst-1 et un analogue de cytidineInfo
- Publication number
- MA49627A MA49627A MA049627A MA49627A MA49627A MA 49627 A MA49627 A MA 49627A MA 049627 A MA049627 A MA 049627A MA 49627 A MA49627 A MA 49627A MA 49627 A MA49627 A MA 49627A
- Authority
- MA
- Morocco
- Prior art keywords
- bst
- cytidine
- analogue
- antibody
- combinations including
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1711785.4A GB201711785D0 (en) | 2017-07-21 | 2017-07-21 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49627A true MA49627A (fr) | 2020-05-27 |
Family
ID=59771583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049627A MA49627A (fr) | 2017-07-21 | 2018-07-20 | Associations pharmaceutiques comprenant un anticorps anti-bst-1 et un analogue de cytidine |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20200231694A1 (https=) |
| EP (1) | EP3655033A1 (https=) |
| JP (1) | JP2020527594A (https=) |
| KR (1) | KR20200032162A (https=) |
| CN (1) | CN111132697A (https=) |
| AR (1) | AR112460A1 (https=) |
| AU (1) | AU2018303241A1 (https=) |
| BR (1) | BR112020001320A2 (https=) |
| CA (1) | CA3070264A1 (https=) |
| CL (1) | CL2020000175A1 (https=) |
| CO (1) | CO2020001792A2 (https=) |
| EA (1) | EA202090333A1 (https=) |
| GB (1) | GB201711785D0 (https=) |
| IL (1) | IL272096A (https=) |
| MA (1) | MA49627A (https=) |
| MX (1) | MX2020000752A (https=) |
| PH (1) | PH12020550024A1 (https=) |
| SG (1) | SG11202000390TA (https=) |
| TW (1) | TW201907952A (https=) |
| UY (1) | UY37815A (https=) |
| WO (1) | WO2019016371A1 (https=) |
| ZA (1) | ZA202000881B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| UA114478C2 (uk) * | 2011-06-28 | 2017-06-26 | Берлін-Хемі Аг | Антитіло, яке специфічно зв'язується з bst1 |
| GB201806084D0 (en) * | 2018-04-13 | 2018-05-30 | Berlin Chemie Ag | Antibodies |
| CN114555123B (zh) * | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
-
2017
- 2017-07-21 GB GBGB1711785.4A patent/GB201711785D0/en not_active Ceased
-
2018
- 2018-07-20 TW TW107125058A patent/TW201907952A/zh unknown
- 2018-07-20 UY UY0001037815A patent/UY37815A/es not_active Application Discontinuation
- 2018-07-20 EP EP18746656.0A patent/EP3655033A1/en not_active Withdrawn
- 2018-07-20 AR ARP180102042 patent/AR112460A1/es not_active Application Discontinuation
- 2018-07-20 MA MA049627A patent/MA49627A/fr unknown
- 2018-07-20 CN CN201880060959.0A patent/CN111132697A/zh active Pending
- 2018-07-20 SG SG11202000390TA patent/SG11202000390TA/en unknown
- 2018-07-20 MX MX2020000752A patent/MX2020000752A/es unknown
- 2018-07-20 WO PCT/EP2018/069768 patent/WO2019016371A1/en not_active Ceased
- 2018-07-20 US US16/632,195 patent/US20200231694A1/en not_active Abandoned
- 2018-07-20 BR BR112020001320-0A patent/BR112020001320A2/pt not_active IP Right Cessation
- 2018-07-20 CA CA3070264A patent/CA3070264A1/en active Pending
- 2018-07-20 AU AU2018303241A patent/AU2018303241A1/en not_active Abandoned
- 2018-07-20 EA EA202090333A patent/EA202090333A1/ru unknown
- 2018-07-20 JP JP2020503018A patent/JP2020527594A/ja not_active Withdrawn
- 2018-07-20 KR KR1020207005030A patent/KR20200032162A/ko not_active Withdrawn
-
2020
- 2020-01-16 IL IL272096A patent/IL272096A/en unknown
- 2020-01-16 PH PH12020550024A patent/PH12020550024A1/en unknown
- 2020-01-20 CL CL2020000175A patent/CL2020000175A1/es unknown
- 2020-02-11 ZA ZA2020/00881A patent/ZA202000881B/en unknown
- 2020-02-18 CO CONC2020/0001792A patent/CO2020001792A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201711785D0 (en) | 2017-09-06 |
| SG11202000390TA (en) | 2020-02-27 |
| ZA202000881B (en) | 2021-08-25 |
| BR112020001320A2 (pt) | 2020-08-11 |
| MX2020000752A (es) | 2020-08-17 |
| AR112460A1 (es) | 2019-10-30 |
| EA202090333A1 (ru) | 2020-05-06 |
| IL272096A (en) | 2020-03-31 |
| WO2019016371A1 (en) | 2019-01-24 |
| CL2020000175A1 (es) | 2020-06-12 |
| TW201907952A (zh) | 2019-03-01 |
| CN111132697A (zh) | 2020-05-08 |
| EP3655033A1 (en) | 2020-05-27 |
| AU2018303241A1 (en) | 2020-02-20 |
| UY37815A (es) | 2019-02-28 |
| CO2020001792A2 (es) | 2020-07-31 |
| CA3070264A1 (en) | 2019-01-24 |
| US20200231694A1 (en) | 2020-07-23 |
| PH12020550024A1 (en) | 2021-02-15 |
| KR20200032162A (ko) | 2020-03-25 |
| JP2020527594A (ja) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3626825A4 (en) | ANTI-CDH6 ANTIBODIES AND ANTI-CDH6 ANTIBODY INGREDIENT CONJUGATE | |
| EP3618871A4 (en) | FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES | |
| MA55206A (fr) | Polyribonucléotides circulaires et compositions pharmaceutiques associées | |
| EP3723803A4 (en) | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES | |
| EP3436482A4 (en) | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS | |
| EP3658589C0 (en) | Anti-sirp-alpha antibodies and related methods | |
| EP4047019A4 (en) | Anti-tslp antibody and uses thereof | |
| MA49977A (fr) | Combinaisons pharmaceutiques comprenant un anticorps anti-ly75 | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| EP3999545A4 (en) | ANTI-CD73 ANTIBODIES AND USE THEREOF | |
| EP3572428A4 (en) | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| EP3638248A4 (en) | CONJUGATES OF PHARMACEUTICAL INGREDIENTS | |
| EP3735427A4 (en) | ANTI-MCT1 ANTIBODIES AND USES THEREOF | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| EP3941946A4 (en) | CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES | |
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| EP3845244A4 (en) | ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE | |
| EP3518971A4 (en) | ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF | |
| EP3733702A4 (en) | ANTI-LAG-3 ANTIBODIES AND USES THEREOF | |
| EP3500255A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE | |
| EP3599249A4 (en) | ANTI-5T4 ANTIBODY MEDICINAL CONJUGATE AND USES THEREOF | |
| EP3675863A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH SEPIAPTERIN AND USES THEREOF | |
| EP3625262A4 (en) | ANTI-FOLR1 IMMUNE CONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS | |
| MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées |